Publication:
Glycated Hemoglobin and Subclinical Atherosclerosis in People Without Diabetes

dc.contributor.authorRossello, Xavier
dc.contributor.authorRaposeiras-Roubin, Sergio
dc.contributor.authorOliva, Belén
dc.contributor.authorSanchez-Cabo, Fatima
dc.contributor.authorGarcía-Ruíz, José M
dc.contributor.authorCaimari, Francisca
dc.contributor.authorMendiguren, José M
dc.contributor.authorLara-Pezzi, Enrique
dc.contributor.authorBueno, Hector
dc.contributor.authorFernández-Friera, Leticia
dc.contributor.authorFernández-Ortiz, Antonio
dc.contributor.authorSanz, Javier
dc.contributor.authorIbáñez, Borja
dc.contributor.authorFuster, Valentin
dc.contributor.funderBanco Santander
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.contributor.funderMinisterio de Ciencia e Innovación (España)
dc.contributor.funderFundación ProCNIC
dc.contributor.funderBayer Healthcare Pharmaceuticals-Bayer Pharma AG
dc.contributor.funderNovartis
dc.contributor.funderFerrer
dc.contributor.funderMedscape
dc.contributor.funderJanssen Cilag
dc.contributor.funderAstraZeneca
dc.contributor.funderUnión Europea. Comisión Europea. European Research Council (ERC)
dc.date.accessioned2023-07-06T09:49:57Z
dc.date.available2023-07-06T09:49:57Z
dc.date.issued2021-06-08
dc.description.abstractBackground: The metabolic injury caused by protein glycation, monitored as the level of glycated hemoglobin (HbA1c), is not represented in most risk scores (i.e., Systematic Coronary Risk Estimation or atherosclerotic cardiovascular disease risk scale). Objectives: The purpose of this study was to assess the association between HbA1c and the extent of subclinical atherosclerosis (SA) and to better identify individuals at higher risk of extensive SA using HbA1c on top of key cardiovascular risk factors (CVRFs). Methods: A cohort of 3,973 middle-aged individuals from the PESA (Progression of Early Subclinical Atherosclerosis) study, with no history of cardiovascular disease and with HbA1c in the nondiabetic range, were assessed for the presence and extent of SA by 2-dimensional vascular ultrasound and noncontrast cardiac computed tomography. Results: After adjusting for established CVRFs, HbA1c showed an association with the multiterritorial extent of SA (odds ratio: 1.05, 1.27, 1.27, 1.36, 1.80, 1.87, and 2.47 for HbA1c 4.9% to 5.0%, 5.1% to 5.2%, 5.3% to 5.4%, 5.5% to 5.6%, 5.7% to 5.8%, 5.9% to 6.0%, and 6.1% to 6.4%, respectively; reference HbA1c ≤4.8%; p < 0.001). The association was significant in all pre-diabetes groups and even below the pre-diabetes cut-off (HbA1c 5.5% to 5.6% odds ratio: 1.36 [95% confidence interval: 1.03 to 1.80]; p = 0.033). High HbA1c was associated with an increased risk of SA in low-risk individuals (p < 0.001), but not in moderate-risk individuals (p = 0.335). Relative risk estimations using Systematic Coronary Risk Estimation or atherosclerotic cardiovascular disease predictors confirmed that inclusion of HbA1c modified the risk of multiterritorial SA in most risk categories. Conclusions: Routine use of HbA1c can identify asymptomatic individuals at higher risk of SA on top of traditional CVRFs. Lifestyle interventions and novel antidiabetic medications might be considered to reduce both HbA1c levels and SA in individuals without diabetes.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThe PESA study is funded by the Centro Nacional de Investigaciones Cardiovasculares (CNIC) and Banco Santander. The study also receives funding from the Instituto de Salud Carlos III (ISCIII, PI15/ 02019, PI17/00590, and PI20/00819) and the European Regional Development Fund (ERDF) “A way to make Europe.” The CNIC is supported by the ISCIII, the Ministerio de Ciencia e Innovación, and the Pro CNIC Foundation. Dr. Bueno has received grants from the Instituto de Salud Carlos III; has received consultancy fees from Bayer, Novartis, Ferrer, MEDSCAPE-the Heart-org, and Janssen; has received grants, consultancy fees, and nonfinancial support from AstraZeneca; and has received grants and consultancy fees from Bristol Myers Squibb-Pfizer, all unrelated to the present study. Dr. Ibanez is supported by the European Commission (ERC-CoG grant No 819775), the Spanish Ministry of Science and Innovation (MCN, ‘RETOS 2019’ grant No PID2019-107332RB-I00), and the Comunidad de Madrid (S2017/BMD-3867 RENIM-CM). The funders had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; the preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.es_ES
dc.format.number22es_ES
dc.format.page2777es_ES
dc.format.volume77es_ES
dc.identifier.citationJ Am Coll Cardiol. 2021 Jun 8;77(22):2777-2791es_ES
dc.identifier.doi10.1016/j.jacc.2021.03.335es_ES
dc.identifier.e-issn1558-3597es_ES
dc.identifier.journalJournal of the American College of Cardiologyes_ES
dc.identifier.otherhttps://hdl.handle.net/20.500.13003/19608
dc.identifier.pubmedID34082907es_ES
dc.identifier.puiL2012106163
dc.identifier.scopus2-s2.0-85106389338
dc.identifier.urihttp://hdl.handle.net/20.500.12105/16211
dc.identifier.wos659328500003
dc.language.isoenges_ES
dc.publisherElsevier
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PI15/02019es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PI17/00590es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PI20/00819es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PID2019-107332RB-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/S2017/BMD-3867es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/ERC-CoG/819775es_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.jacc.2021.03.335es_ES
dc.repisalud.institucionCNICes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Laboratorio Traslacional para la Imagen y Terapia Cardiovasculares_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectGlycated hemoglobin (HbA1c)
dc.subjectPre-diabetes
dc.subjectSubclinical atherosclerosis
dc.subjectDiabetes
dc.subject.decsUltrasonografía
dc.subject.decsTomografía Computarizada por Rayos X
dc.subject.decsEnfermedades Asintomáticas
dc.subject.decsFactores de Riesgo Cardiometabólico
dc.subject.decsHemoglobina A Glucada
dc.subject.decsMasculino
dc.subject.decsAterosclerosis
dc.subject.decsHumanos
dc.subject.decsPersona de Mediana Edad
dc.subject.decsGlucemia
dc.subject.decsEstudios Prospectivos
dc.subject.decsArterias
dc.subject.decsMedición de Riesgo
dc.subject.decsTécnicas de Imagen Cardíaca
dc.subject.decsAdulto
dc.subject.decsPlaca Aterosclerótica
dc.subject.meshAsymptomatic Diseaseses_ES
dc.subject.meshCardiometabolic Risk Factorses_ES
dc.subject.meshAdultes_ES
dc.subject.meshArterieses_ES
dc.subject.meshAtherosclerosises_ES
dc.subject.meshBlood Glucosees_ES
dc.subject.meshCardiac Imaging Techniqueses_ES
dc.subject.meshFemalees_ES
dc.subject.meshGlycated Hemoglobines_ES
dc.subject.meshHumanses_ES
dc.subject.meshMalees_ES
dc.subject.meshMiddle Agedes_ES
dc.subject.meshPlaque, Atherosclerotices_ES
dc.subject.meshProspective Studieses_ES
dc.subject.meshRisk Assessmentes_ES
dc.subject.meshTomography, X-Ray Computedes_ES
dc.subject.meshUltrasonographyes_ES
dc.subject.meshFemenino
dc.titleGlycated Hemoglobin and Subclinical Atherosclerosis in People Without Diabeteses_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicationbbc835c4-284a-4845-8a6e-adf765b43cc1
relation.isAuthorOfPublicationecd7f1e7-2399-4c06-bbc6-d1a2e86c0fbe
relation.isAuthorOfPublicatione7d4df9b-2306-4955-ba22-17d066e07612
relation.isAuthorOfPublication4e417023-fc1f-41d2-8130-485f76466465
relation.isAuthorOfPublication465de6aa-7383-4ba5-b278-765f894f2c87
relation.isAuthorOfPublication2cac8bb6-2bff-4bf6-8209-bdbd21781786
relation.isAuthorOfPublication558474d4-85be-4127-bda8-59128f707249
relation.isAuthorOfPublication.latestForDiscoverybbc835c4-284a-4845-8a6e-adf765b43cc1
relation.isFunderOfPublication2302598f-47dd-49b5-a26e-ae31bf61786e
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublicationefa64f05-b985-4984-8f1e-5fc4ef21f502
relation.isFunderOfPublication289dce42-6a28-4892-b0a8-c70c46cbb185
relation.isFunderOfPublicationef935eeb-4c46-446a-868e-66e905683e75
relation.isFunderOfPublication8012b4b2-5fc6-4177-a486-960d427d8bf5
relation.isFunderOfPublication72800632-4d0e-454d-9663-024ab913e173
relation.isFunderOfPublicationdab5eba3-4825-43e8-85d8-8e885b32b9a8
relation.isFunderOfPublicationfa937537-f1d2-463a-82bc-60c82a583892
relation.isFunderOfPublication47371800-429b-4096-bec8-4520c9e96189
relation.isFunderOfPublicationad910032-f554-423a-818c-cefad228cb97
relation.isFunderOfPublicationcb2ee04a-8d42-4a64-b3f6-3c156f222b35
relation.isFunderOfPublication.latestForDiscovery2302598f-47dd-49b5-a26e-ae31bf61786e
relation.isPublisherOfPublication7d471502-7bd5-4f7a-90a4-8274382509ef
relation.isPublisherOfPublication.latestForDiscovery7d471502-7bd5-4f7a-90a4-8274382509ef

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Glycated Hemoglobin and Subclinical_J Am Coll Cardiol_2021.pdf
Size:
814.47 KB
Format:
Adobe Portable Document Format
Description:
Artículo